Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.
Publication
, Journal Article
Hudson, KE; Rizzieri, D; Thomas, SM; LeBlanc, TW; Powell, Z; Diehl, L; Moore, JO; DeCastro, C; Beaven, AW
Published in: Br J Haematol
February 2019
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Br J Haematol
DOI
EISSN
1365-2141
Publication Date
February 2019
Volume
184
Issue
4
Start / End Page
647 / 650
Location
England
Related Subject Headings
- Survival Rate
- Rituximab
- Risk Factors
- Middle Aged
- Male
- Lymphoma, Mantle-Cell
- Lymphoma, Large B-Cell, Diffuse
- Immunotherapy
- Immunology
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Hudson, K. E., Rizzieri, D., Thomas, S. M., LeBlanc, T. W., Powell, Z., Diehl, L., … Beaven, A. W. (2019). Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol, 184(4), 647–650. https://doi.org/10.1111/bjh.15138
Hudson, Kathryn E., David Rizzieri, Samantha M. Thomas, Thomas W. LeBlanc, Zachary Powell, Louis Diehl, Joseph O. Moore, Carlos DeCastro, and Anne W. Beaven. “Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.” Br J Haematol 184, no. 4 (February 2019): 647–50. https://doi.org/10.1111/bjh.15138.
Hudson KE, Rizzieri D, Thomas SM, LeBlanc TW, Powell Z, Diehl L, et al. Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol. 2019 Feb;184(4):647–50.
Hudson, Kathryn E., et al. “Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.” Br J Haematol, vol. 184, no. 4, Feb. 2019, pp. 647–50. Pubmed, doi:10.1111/bjh.15138.
Hudson KE, Rizzieri D, Thomas SM, LeBlanc TW, Powell Z, Diehl L, Moore JO, DeCastro C, Beaven AW. Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol. 2019 Feb;184(4):647–650.
Published In
Br J Haematol
DOI
EISSN
1365-2141
Publication Date
February 2019
Volume
184
Issue
4
Start / End Page
647 / 650
Location
England
Related Subject Headings
- Survival Rate
- Rituximab
- Risk Factors
- Middle Aged
- Male
- Lymphoma, Mantle-Cell
- Lymphoma, Large B-Cell, Diffuse
- Immunotherapy
- Immunology
- Humans